JPRN-UMIN000005210招募中2 期
eoadjuvant trastuzumab and nab-paclitaxel for HER2 positive breast cancer. - Neoadjuvant trastuzumab and nab-paclitaxel for HER2 positive breast cancer.
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) During pregnancy or lactation 2) Previous (written 5 years) or current history of malignant neoplasm 3) Sever bone marrow suppression, renal dysfunction, and liver dysfunction . 4) Long-term corticosteroid therapy 5) Sever cardiovascular or pulmonary disease. 6) Drug allergy to nab-paclitaxel or paclitaxel and albumin.
研究者
相似试验
已完成
2 期
Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN StudyHER2 PositiveBreast CancerNCT00768859The Netherlands Cancer Institute111
进行中（未招募）
不适用
Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study - TRAIN studyHER2 positive breat cancerMedDRA version: 9.1Level: LLTClassification code 10006187Term: Breast cancerEUCTR2008-000987-18-NLetherlands Cancer Institute
进行中（未招募）
1 期
Effectiveness of olaparib plus trastuzumab in advanced breast cancer patientsEUCTR2018-001213-32-ESMedica Scientia Innovation Research (MedSIR)33
招募中
2 期
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast CancerHER2-positive Breast CancerInvasive Carcinoma of the BreastNode Negative Breast CancerMicrometastasis Breast CancerHormone Receptor Positive Breast CancerBreast CancerNCT04569747Dana-Farber Cancer Institute375
已完成
不适用
Trastuzumab incombination with S-1/CDDP of HER2-positive advanced gastric cancer: a phase II trial.HER2 positive gastric cancerJPRN-UMIN000005792Dept. of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences30